August 2012
-
Molex, which describes itself as “a global manufacturer of complete interconnect solutions,” will acquire device developer and manufacturer Phillips-Medisize from Golden Gate Capital, the company said. The financial terms of were not disclosed. Phillips-Medisize was… Read more . . .
-
Johnson & Johnson has announced that intransal esketamine being developed by its subsidiary Janssen Research & Development has received Breakthrough Therapy Designation from the FDA. According to J&J, the product is in Phase 3 development… Read more . . .
-
Cannabis Science, which recently announced that it would introduce a THC/CBD product for use in nebulizers by asthma/COPD patients, now says that it plans to market a metered dose inhaler called the CBIS MDI Rescue… Read more . . .
-
Johnson & Johnson spinout PrEP Biopharm has announced that former GSK Global Head of Analytical Technologies Anna Slater has joined the company as Head of Chemistry, Manufacturing and Controls. At GSK, Slater had been a… Read more . . .
-
Arch Biopartners has announced that Catalent Inhalation will begin the process of manufacturing its AB569 bactericidal inhalation solution for use in trials of the drug in patients with antibiotic resistant lung infections. The process will… Read more . . .
-
AstraZeneca has announced top-line results from the Phase 3 RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) and CHASE 3 (ChildHood Asthma Safety and Efficacy) studies of the Symbicort budesonide/formoterol fumarate MDI… Read more . . .
-
A Q&A with Kristian Debus and Prashanth Shankara of CD-adapco Q: Doesn’t optimization of drug delivery devices using computer simulation require a lot of time and resources? KD: Actually, these days you can optimize an… Read more . . .
-
Windtree Therapeutics has received $1 million from a Phase 2 Small Business Innovation Research Grant (SBIR) worth up to $2.6 million for a Phase 2b trial of its Aerosurf aerosolized KL4 surfactant in premature infants… Read more . . .
-
Dr. Reddy’s Laboratories has acquired tobramycin inhalation solution from Teva Pharmaceutical Industries as part of the divestiture required by the US Federal Trade Commission (FTC) before Teva could acquire Allergan’s generics business. Teva received FDA… Read more . . .
-
Adamis Pharmaceuticals says that it has received additional US and European patents for the Taper dry powder inhaler, which the company acquired from 3M Drug Delivery Systems in 2013. In January 2015, Adamis announced that… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland